Si-Bone is a San Jose, CA-based company dedicated to developing tools and products for patients with low back issues related to certain sacroiliac (SI) joint disorders. Its core product, the iFuse Implant System, is a minimally invasive surgical option that uses titanium implants coated with a porous titanium plasma spray (TPS) to decrease implant motion and allow biological fixation for long-term fusion. The system is intended for sacroiliac fusion for conditions including SI joint dysfunction resulting from joint disruption and degenerative sacroiliitis. Si-Bone received FDA 510(k) clearance for the iFuse Implant System in November 2008 and obtained a CE mark for European commercialization in November 2010. The company is led by President and CEO Jeffrey Dunn and founder/CMO Mark A. Reiley, MD. Financially, the company raised $20M in a financing disclosed via an SEC filing, with nine unnamed investors participating and an update noting the round was led by Arboretum Ventures with participation from existing major investors. Si-Bone is a medical device company based in San Jose, California, that manufactures the iFuse Implant System, a minimally invasive surgical device indicated for fusion for certain disorders of the sacroiliac (SI) joint. The company is led by President and CEO Jeffrey Dunn. It closed a $21M growth capital financing to support its expansion plans. Si-Bone intends to use the funds to further expand in the U.S. and Europe and to enter the Middle East, Asia and South America. The financing was positioned as growth capital to fuel geographic expansion and commercial activities. No revenue or user metrics were disclosed in the article. SI-BONE develops tools and products for diagnosing and treating patients with low back issues related to sacroiliac (SI) joint disorders, led by President and CEO Jeffrey Dunn. Its core product is the iFuse Implant System®, which received FDA 510(k) clearance in November 2008 for fracture fixation and an additional clearance in April 2011 for sacroiliac joint fusion; the system obtained CE mark in November 2010. The iFuse procedure uses a small incision to deliver titanium implants coated with a porous titanium plasma spray designed to decrease implant motion, provide immediate fixation and allow biological fixation for long-term fusion. The company is conducting three prospective clinical studies: SIFI (U.S. multicenter single arm), INSITE (U.S. multicenter randomized) and iMIA (European multicenter randomized). SI-BONE intends to expand its U.S. sales organization and add resources in R&D, medical affairs, regulatory, compliance and reimbursement. It also plans to pursue regulatory approvals in over a dozen countries in Asia, the Middle East and South America and initiate commercialization in Australia, New Zealand and Hong Kong. SI-BONE is a San Jose, California-based medical device company that develops and commercializes the iFuse Implant System. iFuse is a minimally invasive surgical (MIS) device for treatment of sacroiliac joint pathology and is commercially available in the U.S. for sacroiliac joint disruptions and degenerative sacroiliitis. The procedure uses a minimal incision to deliver and implant small titanium implants coated with a porous plasma spray that acts as an interference surface designed to help decrease implant motion. The company closed a $16.0M financing round led by Montreux Equity Partners with participation from Skyline Ventures. SI-BONE intends to use the funds to expand clinical and commercial operations and to ramp up iFuse adoption. In conjunction with the financing, John Savarese, M.D., of Montreux will join SI-BONE’s board; the company is led by CEO Jeff Dunn. SI-BONE is a San Jose, California-based spinal medical device company focused on diagnosing and treating low back issues related to sacroiliac joint pathology. Its core product is the iFuse Implant System, a commercially available device in the US intended for fracture fixation of large pelvic bones and bone fragments for sacroiliac joint disruptions and degenerative sacroiliitis. The company closed $11.0m in venture capital financing led by new investor Skyline Ventures. The funding will allow SI-BONE to expand its clinical and commercial operations to market the iFuse Implant System. As part of the financing, Glenn Reicin, a partner at Skyline Ventures, will join SI-BONE’s Board of Directors.

Total raised

$101M

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2016